- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Examining the Future: Journey Medical's Earnings Outlook | 1 | Benzinga.com | ||
| Do | Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 | 3 | GlobeNewswire (USA) | ||
| 05.08. | Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 | 1 | GlobeNewswire (USA) | ||
| 14.07. | Journey Medical Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 14.07. | Journey Medical's rosacea treatment reaches 65% commercial coverage | 2 | Investing.com | ||
| 14.07. | Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi | 2 | GlobeNewswire (USA) | ||
| 24.06. | Journey Medical to join Russell 2000 and 3000 indexes | 3 | Investing.com | ||
| 24.06. | Journey Medical Corporation: Journey Medical to Join Russell 2000 and Russell 3000 Indexes | 1 | GlobeNewswire (USA) | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 24.06. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Journey Medicals Rosacea-Medikament zeigt Wirksamkeit unabhängig vom Gewicht | 1 | Investing.com Deutsch | ||
| 09.06. | Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV | 2 | GlobeNewswire (USA) | ||
| 15.05. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 15.05. | Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M | 2 | Seeking Alpha | ||
| 15.05. | Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025 | 2 | Seeking Alpha | ||
| 14.05. | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 117 | GlobeNewswire (Europe) | Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen | |
| 07.05. | Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 | 2 | GlobeNewswire (USA) | ||
| 30.04. | Why Journey Medical Corporation (DERM) is Surging in 2025 | 1 | Insider Monkey | ||
| 03.04. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 01.04. | Journey Medical appoints Ramsey Alloush as COO | 1 | Seeking Alpha | ||
| 01.04. | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 122 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,200 | -0,02 % | BioNTech-Partner Pfizer schlägt die Erwartungen - Prognose rauf | Mit dem US-Unternehmen Pfizer hat der nächste große Pharma-Player die Zahlen zum abgelaufenen zweiten Quartal vorgelegt. Der Partner der Mainzer Biotech-Firma BioNTech wird mit Blick auf das laufende... ► Artikel lesen | |
| GILEAD SCIENCES | 103,50 | -0,35 % | Starke Zahlen, angehobener Ausblick und günstige Bewertung: Gilead Sciences weiß zu überzeugen! | Das US-Biotechunternehmen Gilead Sciences hat am Donnerstagabend starke Zahlen vorgelegt. Die Aktie bietet Anlegerinnen und Anlegern ein attraktives Gesamtpaket. Diese Quartalssaison ist für Biotechwerte... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 323,45 | +0,20 % | Studie eingestellt: Vertex Pharmaceuticals crasht trotz starker Quartalszahlen! | Die Aktie von Vertex Pharmaceuticals steht am Dienstag vor empfindlichen Verlusten. Starke Quartalszahlen werden von einer eingestellten Studie überschattet. Vertex Pharmaceuticals: Einer der konstantesten... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 8,604 | -2,82 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments | - Completed Phase 3 enrollment for DURAVYU in wet AMD with over 800 patients enrolled and randomized - - LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician... ► Artikel lesen | |
| ROCKET LAB | 38,800 | -0,51 % | Rocket Lab USA - RKLB: Startet die Raketen-Aktie nach den Quartalszahlen durch? >> PULLBACK-SETUP !!! | Earnings heute 4:15 PM ET! Skalierung mit der Electron- oder mehr Nutzlast mit der Neutron-Rakete? Wann wird Rocket Lab USA (RKLB) endlich profitabel ? Rocket Lab USA (RKLB) - ISIN US7731221062 Rückblick:... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 5,250 | -9,48 % | Astria Therapeutics licenses navenibart rights to Kaken for HAE | ||
| OPKO HEALTH | 1,093 | -2,03 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 128,00 | +0,79 % | Ligand Pharmaceuticals: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance | Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million)... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 95,26 | -0,25 % | Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma | Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adultsAccelerated approval based on an overall response... ► Artikel lesen | |
| ROYALTY PHARMA | 32,020 | +2,63 % | Royalty Pharma Plc Q2 Income Retreats | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) released a profit for second quarter that Drops, from the same period last yearThe company's earnings came in at $30.17 million, or $0.07 per... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 16,935 | -0,24 % | Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion | ||
| TG THERAPEUTICS | 22,700 | -0,29 % | TG THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CORBUS PHARMACEUTICALS | 7,650 | +2,68 % | Corbus Pharma's Q2 Net Loss Widens | ||
| CATALENT | 59,93 | 0,00 % | BMO Capital lowers Scholar Rock stock price target to $45 on Novo Catalent concerns | ||
| TALPHERA | 0,357 | -2,33 % | Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 7,940 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.